| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.
|
Cancer Cell
|
2006
|
15.16
|
|
2
|
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
|
J Clin Oncol
|
2008
|
8.79
|
|
3
|
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain.
|
Cancer Cell
|
2006
|
8.09
|
|
4
|
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.
|
Neuro Oncol
|
2008
|
4.39
|
|
5
|
SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma.
|
Cell Stem Cell
|
2009
|
3.89
|
|
6
|
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells.
|
Cancer Cell
|
2008
|
3.87
|
|
7
|
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation.
|
Cancer Res
|
2005
|
3.63
|
|
8
|
Rembrandt: helping personalized medicine become a reality through integrative translational research.
|
Mol Cancer Res
|
2009
|
3.58
|
|
9
|
Scale to predict survival after surgery for recurrent glioblastoma multiforme.
|
J Clin Oncol
|
2010
|
2.67
|
|
10
|
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
|
Cancer Discov
|
2012
|
2.61
|
|
11
|
High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances.
|
Cancer Res
|
2006
|
2.56
|
|
12
|
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
|
Neuro Oncol
|
2006
|
2.49
|
|
13
|
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
|
J Clin Oncol
|
2010
|
2.45
|
|
14
|
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
|
Clin Cancer Res
|
2006
|
2.44
|
|
15
|
Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes.
|
Cancer Res
|
2009
|
2.42
|
|
16
|
Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas.
|
Mol Cancer Res
|
2008
|
2.22
|
|
17
|
Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation.
|
Cancer Res
|
2008
|
2.16
|
|
18
|
Primary central nervous system lymphoma: time to ask the question.
|
J Clin Oncol
|
2002
|
1.92
|
|
19
|
Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion.
|
J Natl Cancer Inst
|
2011
|
1.86
|
|
20
|
Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury.
|
J Clin Invest
|
2004
|
1.85
|
|
21
|
Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model.
|
Blood
|
2004
|
1.76
|
|
22
|
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
|
Hum Gene Ther
|
2012
|
1.75
|
|
23
|
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
|
Neuro Oncol
|
2009
|
1.66
|
|
24
|
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy.
|
Glia
|
2011
|
1.63
|
|
25
|
History of allergies and autoimmune diseases and risk of brain tumors in adults.
|
Int J Cancer
|
2002
|
1.62
|
|
26
|
Predicting in vitro drug sensitivity using Random Forests.
|
Bioinformatics
|
2010
|
1.59
|
|
27
|
DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma.
|
Neuro Oncol
|
2009
|
1.51
|
|
28
|
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
|
Neuro Oncol
|
2011
|
1.50
|
|
29
|
Reproductive and hormonal factors and risk of brain tumors in adult females.
|
Int J Cancer
|
2005
|
1.50
|
|
30
|
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
|
Neuro Oncol
|
2010
|
1.46
|
|
31
|
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
|
J Clin Oncol
|
2009
|
1.41
|
|
32
|
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
|
Neuro Oncol
|
2004
|
1.33
|
|
33
|
Notch-1 regulates transcription of the epidermal growth factor receptor through p53.
|
Carcinogenesis
|
2008
|
1.33
|
|
34
|
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
|
Neuro Oncol
|
2009
|
1.30
|
|
35
|
Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
1.28
|
|
36
|
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.
|
Arch Dermatol
|
2009
|
1.23
|
|
37
|
Lead, genetic susceptibility, and risk of adult brain tumors.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
1.23
|
|
38
|
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
|
J Neurooncol
|
2009
|
1.21
|
|
39
|
FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway.
|
Neoplasia
|
2008
|
1.21
|
|
40
|
Integration and analysis of genome-scale data from gliomas.
|
Nat Rev Neurol
|
2011
|
1.20
|
|
41
|
Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
1.17
|
|
42
|
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma.
|
Neuro Oncol
|
2003
|
1.15
|
|
43
|
Oxidative response gene polymorphisms and risk of adult brain tumors.
|
Neuro Oncol
|
2008
|
1.13
|
|
44
|
Prediction of Associations between microRNAs and Gene Expression in Glioma Biology.
|
PLoS One
|
2011
|
1.10
|
|
45
|
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2004
|
1.09
|
|
46
|
Many tumors in one: a daunting therapeutic prospect.
|
Cancer Cell
|
2011
|
1.09
|
|
47
|
Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.
|
Cancer Res
|
2004
|
1.09
|
|
48
|
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.
|
Neuro Oncol
|
2011
|
1.09
|
|
49
|
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.
|
Neuro Oncol
|
2010
|
1.08
|
|
50
|
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
|
Cancer
|
2014
|
1.07
|
|
51
|
Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.
|
Lab Invest
|
2008
|
1.06
|
|
52
|
Correlation analysis between single-nucleotide polymorphism and expression arrays in gliomas identifies potentially relevant target genes.
|
Cancer Res
|
2009
|
1.04
|
|
53
|
Testing of new agents in childhood cancer preclinical models: meeting summary.
|
Clin Cancer Res
|
2002
|
1.03
|
|
54
|
The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas.
|
J Natl Cancer Inst
|
2007
|
1.03
|
|
55
|
Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization.
|
PLoS One
|
2012
|
1.02
|
|
56
|
Bevacizumab for malignant gliomas.
|
Arch Neurol
|
2010
|
1.02
|
|
57
|
Continuous daily sunitinib for recurrent glioblastoma.
|
J Neurooncol
|
2012
|
0.99
|
|
58
|
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
|
Neuro Oncol
|
2004
|
0.99
|
|
59
|
Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.
|
J Neurooncol
|
2011
|
0.99
|
|
60
|
A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
|
Neuro Oncol
|
2012
|
0.97
|
|
61
|
Sociodemographic indicators and risk of brain tumours.
|
Int J Epidemiol
|
2003
|
0.97
|
|
62
|
Cancer in first-degree relatives and risk of glioma in adults.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.97
|
|
63
|
A phase I trial of enzastaurin in patients with recurrent gliomas.
|
Clin Cancer Res
|
2009
|
0.96
|
|
64
|
Common variation in genes related to innate immunity and risk of adult glioma.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
0.96
|
|
65
|
Cellular and genetic characterization of human adult bone marrow-derived neural stem-like cells: a potential antiglioma cellular vector.
|
Cancer Res
|
2003
|
0.96
|
|
66
|
G-cimp status prediction of glioblastoma samples using mRNA expression data.
|
PLoS One
|
2012
|
0.96
|
|
67
|
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
|
Neuro Oncol
|
2009
|
0.94
|
|
68
|
Risk of meningioma and common variation in genes related to innate immunity.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
0.94
|
|
69
|
Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo.
|
Cancer Res
|
2004
|
0.94
|
|
70
|
Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors.
|
Neuro Oncol
|
2006
|
0.93
|
|
71
|
Qualitative network modeling of the Myc-p53 control system of cell proliferation and differentiation.
|
Biophys J
|
2011
|
0.93
|
|
72
|
Monocytes form a vascular barrier and participate in vessel repair after brain injury.
|
Blood
|
2005
|
0.91
|
|
73
|
Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector.
|
Neoplasia
|
2002
|
0.91
|
|
74
|
Occupation and risk of meningioma and acoustic neuroma in the United States.
|
Am J Ind Med
|
2004
|
0.90
|
|
75
|
The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D).
|
Acta Neuropathol Commun
|
2013
|
0.90
|
|
76
|
Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas.
|
Cancer
|
2010
|
0.90
|
|
77
|
Gene pathways and subnetworks distinguish between major glioma subtypes and elucidate potential underlying biology.
|
J Biomed Inform
|
2010
|
0.88
|
|
78
|
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium.
|
Neuro Oncol
|
2008
|
0.88
|
|
79
|
Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort.
|
J Neurooncol
|
2014
|
0.88
|
|
80
|
Genetic variation in insulin-like growth factors and brain tumor risk.
|
Neuro Oncol
|
2008
|
0.87
|
|
81
|
Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc.
|
Cancer Res
|
2012
|
0.87
|
|
82
|
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
|
Neuro Oncol
|
2011
|
0.87
|
|
83
|
FastMEDUSA: a parallelized tool to infer gene regulatory networks.
|
Bioinformatics
|
2010
|
0.85
|
|
84
|
Central nervous system cancers: Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2005
|
0.85
|
|
85
|
Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults.
|
Environ Health Perspect
|
2005
|
0.85
|
|
86
|
Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels.
|
PLoS One
|
2013
|
0.85
|
|
87
|
SnapShot: glioblastoma multiforme.
|
Cancer Cell
|
2012
|
0.85
|
|
88
|
Malignant gliomas: new translational therapies.
|
Mt Sinai J Med
|
2010
|
0.85
|
|
89
|
Occupational exposure to magnetic fields and the risk of brain tumors.
|
Neuro Oncol
|
2009
|
0.84
|
|
90
|
Handedness and risk of brain tumors in adults.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.84
|
|
91
|
Glioma stem cells: better flat than round.
|
Cell Stem Cell
|
2009
|
0.83
|
|
92
|
GliomaPredict: a clinically useful tool for assigning glioma patients to specific molecular subtypes.
|
BMC Med Inform Decis Mak
|
2010
|
0.83
|
|
93
|
Refining endpoints in brain tumor clinical trials.
|
J Neurooncol
|
2012
|
0.83
|
|
94
|
Evaluation of (76)Br-FBAU as a PET reporter probe for HSV1-tk gene expression imaging using mouse models of human glioma.
|
J Nucl Med
|
2005
|
0.82
|
|
95
|
Personal hair dye use and risks of glioma, meningioma, and acoustic neuroma among adults.
|
Am J Epidemiol
|
2006
|
0.82
|
|
96
|
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.
|
Cornea
|
2009
|
0.82
|
|
97
|
Meningioma and schwannoma risk in adults in relation to family history of cancer.
|
Neuro Oncol
|
2004
|
0.81
|
|
98
|
Toward a glioblastoma vaccine: promise and potential pitfalls.
|
J Clin Oncol
|
2004
|
0.80
|
|
99
|
Self-reported electrical appliance use and risk of adult brain tumors.
|
Am J Epidemiol
|
2005
|
0.80
|
|
100
|
Polyomavirus and medulloblastoma: a smoking gun or guilt by association?
|
J Natl Cancer Inst
|
2002
|
0.80
|
|
101
|
Antiangiogenic therapy for primary and metastatic brain tumors.
|
Hematol Oncol Clin North Am
|
2004
|
0.80
|
|
102
|
Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
|
PLoS One
|
2013
|
0.80
|
|
103
|
Spinal cord glioneuronal tumor with neuropil-like islands with 1p/19q deletion in an adult with low-grade cerebral oligodendroglioma.
|
J Neurooncol
|
2011
|
0.80
|
|
104
|
A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).
|
J Neurooncol
|
2012
|
0.79
|
|
105
|
Laterality of brain tumors.
|
Neuroepidemiology
|
2003
|
0.79
|
|
106
|
Polio vaccination and risk of brain tumors in adults: no apparent association.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.79
|
|
107
|
Progress report on the potential of angiogenesis inhibitors for neuro-oncology.
|
Cancer Invest
|
2004
|
0.78
|
|
108
|
CNAReporter: a GenePattern pipeline for the generation of clinical reports of genomic alterations.
|
BMC Med Genomics
|
2010
|
0.78
|
|
109
|
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.76
|
|
110
|
Selected human leukocyte antigen class II polymorphisms and risk of adult glioma.
|
J Neuroimmunol
|
2010
|
0.75
|
|
111
|
The Ids have it.
|
Cancer Cell
|
2010
|
0.75
|
|
112
|
A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2013
|
0.75
|
|
113
|
Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2004
|
0.75
|